Stroke-induced immunodepression is an independent risk factor for stroke-associated pneumonia (SAP). Granulocyte-macrophage colony stimulating factor (GM-CSF) has neuroprotective properties in experimental stroke and been demonstrated to reverse immunodepression in sepsis patients. However, whether GM-CSF restores immune function after stroke preventing SAP and improving outcome is unknown. Here, we demonstrated that GM-CSF treatment improved peripheral and pulmonary leukocyte numbers, peripheral cytokine responses, lowered lung bacterial burden in the early course and improved long-term functional outcome after experimental stroke. These data suggest that GM-CSF is promising for stroke treatment since it not only acts neuroprotective in the ischemic brain but may also protect against detrimental post-stroke infections. 
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Introduction
Major determinants of poor clinical outcome after cerebral ischemia are medical complications among which stroke-associated pneumonia (SAP) is the most frequent and severe complication and the leading cause of death. There is now compelling experimental and clinical evidence that stroke-induced temporary immunodeficiency characterized by a rapid suppression of cellular and humoral immune responses is an independent risk factor of SAP, besides neurological deficits such as dysphagia facilitating aspiration (Chamorro et al. , 2012 , Hoffmann et al. , 2016 , Meisel et al. , 2005 . Despite general measures to prevent aspiration, SAP remains one of the most important modifiable factors for poor outcome in stroke patients. Very recently, two phase III trials have demonstrated that preventive antibiotic therapy neither prevents pneumonia nor improves stroke outcome (Kalra et al. , 2015 , Westendorp et al. , 2015 . Since SAP occurs usually between day 2 and 7, restoring host immunity immediately after stroke onset might be a promising therapeutic strategy to prevent SAP and thereby to improve outcome after stroke . However, since immunodepression after stroke may protect against secondary brain injury by preventing harmful CNS-directed immune responses, immunomodulatory therapies need to be tested rigorously considering long-term consequences for both the brain and body`s periphery . Granulocyte-macrophage colony-stimulating factor (GM-CSF) is a pluripotent cytokine, which increases myelopoiesis but also pro-inflammatory and antimicrobial function of myeloid immune cells. We and others have previously shown that GM-CSF treatment can effectively reverse the state of immunodepression in sepsis patients and decrease the duration of infection in immunosuppressed surgical patients (Hall et al. , 2011 , Meisel et al. , 2009 , Spies et al. , 2015 . In the lung, GM-CSF drives differentiation and function of alveolar macrophages and dendritic cells, and has been shown to be protective in preclinical models of pneumonia-associated lung injury (Herold et al. , 2014 , Unkel et al. , 2012 . Moreover, GM-CSF has been found to exert robust neuroprotective and angiogenic effects in animal models of cerebral ischemia (Lanfranconi et al. , 2011) . However, whether GM-CSF-mediated protective effects in experimental stroke may in part be related to its immunostimulatory properties and the prevention of bacterial infections has not been investigated so far. In attempt to model the clinical situation, we investigated in a preclinical randomized controlled study (Mergenthaler and Meisel, 2012) using the middle cerebral artery occlusion (MCAo) model in mice whether systemic GM-CSF treatment prevents SAP and improves neurological outcome without causing adverse events.
Methods
Animals and housing
Experiments were performed in accordance with the European directive on the protection of animals used for scientific purposes and further applicable legislation, and approved by the relevant authority, Landesamt für Gesundheit und Soziales (LAGeSo), Berlin, Germany. Male specific pathogen free C57Bl/6J mice (Janvier, Saint Berthevin, France) were housed in cages with chip bedding and environmental enrichment on a 12 h light/dark cycle and ad libitum access to standard chow and water.
Experimental stroke (middle cerebral artery occlusion, MCAo)
The middle cerebral artery occlusion (MCAo) was performed as described elsewhere (Engel et al. , 2011) according to the standard operating procedures of the Department of Experimental Neurology, Charité Berlin (Dirnagl, 2010) . In brief, after ventral cervical incision a silicon-coated filament (7019PK5Re, Doccol Corp. Redlands, California, USA) was introduced into the left common carotid artery and advanced to the origin of the middle cerebral artery. The filament was left there for 60 min until reperfusion. Success of MCAo was verified by MRI, and animals without infarct were excluded from the study.
Magnetic resonance imaging (MRI)
A C C E P T E D M A N U S C R I P T Ischemic lesion was quantified using magnetic resonance imaging (Bruker 7 T PharmaScan 70/16) day one and 14 after MCAo (Romer et al. , 2015) .
Application of GM-CSF
Recombinant mGM-CSF (PeproTech, Rocky Hill, USA) was applied subcutaneously (s.c.) at 10µg in 100µl PBS 6, 30 and 54h after MACo (Steinwede et al. , 2011) . Control mice were treated with 100µl PBS s.c.
Microbiological investigation
Analysis of bacterial burden was performed as described elsewhere (Dames et al. , 2014) . In brief, the bronchoscope (Polydiagnost, Pfaffenhofen, Germany) was inserted into the trachea. 200µl saline was pushed from a syringe into the channel of the endoscope. The fluid was withdrawn until no more fluid could be seen in the bronchus. For the determination of colony forming units (CFU), lavage fluid was serially diluted, plated on LB agar plates, incubated at 37°C for 18 h and bacterial colonies counted.
Isolation and ex vivo stimulation of cells
Isolation of lung cells and splenocytes was performed three days after stroke as described elsewhere . Lung single-cell suspensions (2×10 6 /mL), splenocytes (2×10 6 /mL) and whole blood diluted in RPMI with 10% FCS 100 U/mL Penicillin/Streptomycin were stimulated with 10 7 HKEC/mL (Heat Killed E.coli; Invivogen) for 12 h at 37°C. Cytokines in cell culture supernatant were measured by magnetic beadbased assay on a Bio-Plex 200 System (Luminex xMAP Technology) with Bio-Plex Manager 6.0 software (Bio-Rad) according to the manufacturer's recommendations.
Flow cytometry
Cell phenotyping was performed on a LSRII flow cytometer using FACSDiva software (BD Bioscience, Heidelberg, Germany) and FlowJo software (Tree Star Inc., Ashland, USA) with the following anti-mouse monoclonal antibodies: cluster of differentiation (CD) CD11b Phycoerythrine cyanine dye 7 (PE/Cy7), CD11c Pacific-Blue (PB), CD3 Allophycocyanin (APC), CD45 Peridinin chlorophyll protein (PerCP), F4/80 APC, Gr1 Phycoerythrine (PE), SiglecF Phycoerythrine cyanine dye 7 (APC/Cy7) (Biolegend, San Diego, USA or BD Bioscience, Heidelberg, Germany).
Corner Test
Two boards were placed together at a 30° angle to form a narrow alley. The mouse was placed between the boards. As the mouse approached the corner, it turned around to the right or left randomly. The turns in one or the other direction were counted and the laterality index (LI) calculated (Schaar et al. , 2010) .
Catwalk
Gait impairments after stroke were assessed using CatWalk (Noldus, Wageningen, Netherlands) as described previously (Hetze et al. , 2012) .
Methods to prevent bias and exclusion criteria
Treatment allocation was performed randomly and remained blinded for the examiners. Exclusion criteria were unsuccessful stroke based on MRI-investigation and sacrifying before endpoint based on the guidelines on the protection of animals.
Statistics
This study was performed as exploratory study, accordingly the primary analysis was based on descriptive statistics (Kimmelman et al. , 2014) . To obtain a reasonable number of animals, sample size was estimated a priori for immunological examinations as primary and functional outcome as secondary outcome measure applying the program G*Power 3.1.9.2 (Faul et al. , 2007) . 50% improvement in outcome parameters was considered as a relevant effect. For power calculation, we have chosen a power of 80%. All data are expressed as mean + standard deviation (SD). Comparisons between groups were performed with Mann-Whitney test, Student's t-test or two-way ANOVA with Bonferroni Multiple Comparison using solvent treated mice as
control. P-values of p ≤ 0.05 were considered as statistically significant. Statistics were performed using GraphPad Prism 6.0 (GraphPad Prism Software Inc., San Diego, USA).
Results
Impact of systemic GM-CSF on bacterial burden in lung and air-blood barrier function
To investigate the effects of GM-CSF treatment on infarct maturation and spontaneous pneumonia after stroke, GM-CSF or PBS for a control were administered three times subcutaneously, starting 6h after stroke onset. Initial stroke severity measured at day 1 did not differ between both groups ( Figure 1A ). Bronchoalveolar lavage (BAL) 3 days after stroke onset weakly indicated a lower bacterial burden in GM-CSF compared to PBS treated mice ( Figure 1B ; GM-CSF 2.8x10 3 ± 7.4x10 3 , PBS 7.1x10 4 ± 3x10 5 ; p=0.1358). Similarly, the ratio of albumin levels in BAL and serum showed a non-significant reduction in GM-CSF treated mice ( Figure 1C ; GM-CSF 3.5 ± 1.4, PBS 5.3 ± 3.4; p=0.0902), indicating a stabilizing effect of subcutaneous GM-CSF on the alveolar-capillary barrier after experimental stroke.
Systemic GM-CSF treatment increased peripheral and pulmonary leukocyte numbers after stroke but improved cytokine secretion only by peripheral immune cells upon ex vivo TLR stimulation
Pulmonary myeloid and lymphoid cells, particularly neutrophils (Figure 2A , p=0.0597), were increased in GM-CSF (2x10 6 ± 2.8x10 6 ) compared to PBS (3.6x10 5 ± 3.2x10 5 ) treated mice, which was accompanied by a trend towards higher neutrophil numbers in spleen (1.1x10 6 ± 8.7x10
5 ; p=0.0250) and white blood cell counts (3.9x10 3 ± 1.8x10 3 ) of verum mice ( Figure  2B and C). Since GM-CSF is an immunostimulatory cytokine acting on myeloid cells, we assessed the effects of GM-CSF administration on cytokine production by single cell suspension of lung homogenate, spleen and in whole blood after ex vivo stimulation with different TLR ligands. Spleen and whole blood cells from subcutaneously GM-CSF treated stroke mice secreted significantly more pro-inflammatory cytokines after ex vivo HKEC stimulation compared to PBS controls ( Figure 3A and B, p<0.0001). In contrast, we observed no difference in cytokine production by ex vivo stimulated lung cells derived from GM-CSF treated MCAo mice ( Figure 3C ).
GM-CSF treatment improves long-term outcome in stroke mice
To determine a potential positive or negative effect of GM-CSF on neurological outcome we investigated the neurological long-term outcome by assessing gait parameters, sensorimotor function and turning bias. Ten days after stroke gait analysis indicated significantly improved motor function upon GM-CSF treatment. Whereas in the PBS treated group the distance between consecutive steps of the right (RH) and left hind paw (LH) was shortened ( Figure  4A , p=0.04 and p=0.02) and the maximal contact area of the paws decreased ( Figure 4B , p=0.005 and p=0.008) GM-CSF treated MCAo mice showed gait function parameters similar to before stroke ( Figure 4A and B) . Since unilateral stroke results in deficits of sensorimotor function and symmetry, we performed the corner test 17 days after stroke. The laterality index (LI), ratio of turns to the left and right side, was calculated to identify turning bias. PBStreated MCAo mice displayed the stroke related asymmetry and turned more often to the ipsilateral side. In contrast, GM-CSF treated stroke animals showed an average laterality index of 0, indicating equal turns to both sides ( Figure 4C, p=0.04) . To assess the maturation of ischemic brain tissue we analysed changes in infarct volume by MRI from day 1 to day 14 after MCAo. We observed a trend towards smaller infarct sizes in GM-CSF compared to PBS-treated animals ( Figure 4D, p=0.16 ). These findings suggest a positive effect of subcutaneous GM-CSF treatment on functional long-term outcome after experimental stroke. In line with the observed effects on cellularity and function at day 3 post stroke, white blood cell count ( Figure 4E , p=0.04) as well as leukocyte numbers in lung ( Figure 4F ) were increased in GM-CSF compared to PBS-treated MCAo mice indicating that systemic administration of GM-CSF may lead to a sustained recovery of impaired immune function after stroke.
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Discussion
The main finding of the present exploratory study is that GM-CSF treatment within a clinically reasonable time window after stroke augmented antibacterial immune responses and improved neurological long-term outcome after experimental stroke in mice. The importance of this study is that current treatment options fail to effectively protect stroke patients from developing infectious complications. Despite general measures to prevent pneumonia the overall frequency of SAP of about 7% remained largely unchanged over the last decades (Emsley and Hopkins, 2008, Meisel and . Moreover, two recent large clinical trials with more than 3700 patients failed to demonstrate beneficial effect of preventive antibacterial therapy on the incidence of SAP and long-term outcome of stroke patients (Kalra, Irshad, 2015 , Westendorp, Vermeij, 2015 . Thus, novel strategies such as immunostimulatory treatment approaches are of urgent medical need to overcome post-stroke infections and to improve long-term outcome. Stroke induced immunodepression is mainly characterized by an apoptotic loss of lymphocytes, reprogramming of antigen presenting cells such as monocytes with diminished antigen presenting capacity and impaired cytokine release (Chamorro, Meisel, 2012 , Hoffmann, Harms, 2016 . Particularly, a diminished release of proinflammatory cytokines like IFN contributes to the defective antibacterial defence (Prass et al. , 2003 , Wong et al. , 2011 . Similar findings have been shown for other injuries like spinal cord injury, traumatic brain injury and sepsis (Hotchkiss et al. , 2013 , Meisel, Schwab, 2005 , Sarrafzadeh et al. , 2011 . Several studies demonstrated beneficial effects of inhaled GM-CSF for lung function and anti-infective defence as well as for regeneration of injured epithelium by inducing epithelial cell proliferation (Herold, Hoegner, 2014 , Quinton, 2012 . High local concentrations of GM-CSF in bronchoalveolar lavage improve oxygenation, compliance and thereby increasing survival in pneumonia associated ARDS patients. Subcutaneous or intravenous GM-CSF application in sepsis-associated ARDS improved gas exchange and facilitated epithelial cell integrity (Meisel, Schefold, 2009 , Presneill et al. , 2002 . GM-CSF therapy was also shown to counteract sepsis-induced immunodepression (Hall, Knatz, 2011 , Meisel, Schefold, 2009 , Nierhaus et al. , 2003 and to shorten the duration of infections in postoperative immunodepression (Spies, Luetz, 2015) . GM-CSF as well as Granulocyte Colony Stimulating Factor (G-CSF) are widely used to increase myelopoiesis in patients with impaired immune function such as after chemotherapy (Mehta et al. , 2015) . However, while G-CSF rather dampens myeloid cell function, GM-CSF promotes survival, differentiation/maturation and function of myeloid cells including phagocytic activity and cytokine secretion (Hamilton, 2008 , Mehta, Malandra, 2015 , Ringelstein et al. , 2013 . Previous studies in our MCAo model indicate bacteria in lung and blood as early as 12h and 24h, respectively, after stroke onset (Prass, Meisel, 2003) . The kinetic of spontaneous bacterial post-stroke pneumonia together with our observation of a relevant suppression of cellular immune responses (Prass, Meisel, 2003) indicate that therapeutic measures have to be taken within 12-24h after stroke onset in order to be effective. Assuming 6 hours post stroke as feasible time point for hospital admission, diagnosis and treatment onset in patients, we have chosen this time point as the earliest clinically relevant treatment onset in our experimental stroke model. Dosage and application of GM-CSF were chosen based on previously published data (Mehta, Malandra, 2015 , Steinwede, Tempelhof, 2011 . In other diseases associated with immunodepression such as ARDS or sepsis, daily GM-CSF treatment has been shown to reverse the state of immunodepression and to improve lung function (Herold, Hoegner, 2014 , Meisel, Schefold, 2009 , Presneill, Harris, 2002 . In sepsis patients, we observed functional recovery of immune parameters within 2-5 days of GM-CSF administration (Meisel, Schefold, 2009) . Our data indicate that systemic GM-CSF administration early after cerebral ischemia may, at least in part, also reverse stroke-induced immunodepression. Quantification and functionality of immune cells were evaluated day 3
A C C E P T E D M A N U S C R I P T after stroke, because at this time point stroke-induced inhibitory effects on cellular immune responses are most pronounced and there is the highest risk for the occurrence of pulmonary infections in our experimental stroke model as well as in patients (Hannawi et al. , 2013 , Meisel and Smith, 2015 , Meisel, Schwab, 2005 , Prass, Meisel, 2003 . In addition, we assumed the strongest effect of GM-CSF treatment on the recovery of immune function after stroke shortly after the last administration at 54h. Cellularity of lung and blood was additionally assessed 30 days after experimental stoke to investigate long term effects of GM-CSF treatment on leukocyte recruitment and to correlate cellularity with the neurological long-term outcome and infarct size development. GM-CSF not only increased myeloid cells in lung, spleen and blood but also significantly enhanced TLR-induced release of proinflammatory cytokines by splenocytes and peripheral blood immune cells compared to PBStreated stroke mice. However, we observed no significant effect on cytokine production by lung cells. High local GM-CSF concentrations in lung are necessary to improve oxygenation and compliance in ARDS patients (Herold, Hoegner, 2014) . Therefore, it may be possible that GM-CSF levels in the lung upon subcutaneous application were not sufficient to enhance cytokine secretion by pulmonary immune cells. Nevertheless, systemic GM-CSF levels appear to be sufficient to mobilize myeloid cells and recruit neutrophils to the lung. Restored pulmonary myeloid cells accompanied by enhanced splenocytic cytokine secretion seemed to be sufficient to improve pulmonary defense and thereby reduce the susceptibility to pulmonary infections after experimental stroke. Local pulmonary GM-CSF application could further contribute to primary pulmonary defense by inducing epithelial cell proliferation, tissue repair and protecting the host from acute lung injury (Cakarova et al. , 2009) . A broader immunostimulatory approach could be local IFN treatment since its receptor is expressed on immune as well as epithelial and endothelial cells. IFN has already been shown to prevent post-stroke bacterial infection but the effects on the injured brain are largely unknown (Prass, Meisel, 2003) .
Since the blood-brain barrier is impaired after cerebral ischemia, a proinflammatory state may also have detrimental effects to the injured brain. Clinical studies investigating other growth factors like G-CSF in ischemic stroke failed to improve infarct size development and observed adverse effects (Ringelstein, Thijs, 2013) . In this study, infarct sizes were analyzed 1 and 14 days after stroke. Considering infarct maturation, day one is the earliest time point to assess initial infarct size by using MRI. This time point was chosen to exclude stroke severity bias between both treatment groups, whereas analysis day 14 after stroke onset allows evaluating the impact of GM-CSF treatment on resolution and regeneration of injured brain tissue. Our findings are in line with experimental stroke studies suggesting that GM-CSF treatment has no negative impact on infarct maturation. On the contrary, GM-CSF supports resolution and regeneration of injured brain tissue (Buschmann et al. , 2003 , Kong et al. , 2009 , Lanfranconi, Locatelli, 2011 , Schabitz et al. , 2008 , Schneeloch et al. , 2004 , Schneider et al. , 2007 , Sugiyama et al. , 2011 , Theoret et al. , 2016 , Todo et al. , 2008 . Importantly, in our study we observed an improved neurological long-term outcome measured by sensorimotor function 17 days and gait parameter assessments 10 days after stroke being in line with the aforementioned observations. Gait analysis was performed 10 days after MCAo as this time point has been verified as valuable to detect changes in gait pattern and assess the effectiveness of treatment strategies (Hetze, Romer, 2012) , whereas corner test has been confirmed for observation of long-term sensorimotor and postural impairment until 4 weeks after stroke onset (Bouet et al. , 2007 , Schallert, 2006 . As there was no relevant difference in infarct size on day 1 between the groups, the findings cannot be explained by differences in stroke severity. One major limitation of this study is the relatively small number of animals, since we designed our study as exploratory study to evaluate the question whether GM-CSF could be beneficial after stroke at all. The results indicate that GM-CSF could be a promising candidate
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for further research, as it might affect beneficially both neurological outcome and pulmonary immune function.
In conclusion, our findings indicate that early systemic GM-CSF treatment following acute stroke has beneficial effects on the host pulmonary immune response and improves the neurological long-term outcome. This mandates for confirmatory experimental studies, which are necessary for a definitive conclusion.
Figure legends Figure 1 . Impact of subcutaneous GM-CSF treatment on infarct size, spontaneous infections and barrier integrity. GM-CSF (10 µg/mouse) given at 6, 30 and 54 hours after MCAo surgery had no impact on infarct size assessed one day after stroke by MRI (A), whereas bacterial burden in bronchoalveolar lavage by bronchoscopy or post mortem lavage in those sacrificed for ex vivo analysis of functionality (B) and albumin levels (C) three days after stroke tended to be reduced in the GM-CSF compared to the PBS group. Dashed line indicates average values of naïve mice. Values are given as mean ± SD (n=16-19/group for A and B, n=7-9/group for C) compared vs. PBS treated mice using one-tailed Mann-Whitney Test. Figure 2 . Lung, spleen, whole blood and bronchoalveolar lavage cells were isolated and quantified at day 3 after MCAo. Subcutaneous GM-CSF treatment resulted in significant increase of neutrophils in spleen and lung (A, B), whereas cell numbers in spleen (B) and blood (C) showed only a moderate increase or even decrease (D). Values are given as mean ± SD (n=9 mice/ group) and compared using Student's t-test. Figure 3 . In order to assess functionality, lung, spleen cells and whole blood were stimulated ex vivo with HKEC (heat killed E.coli) and cytokines were measured in supernatant at 12hrs. GM-CSF treatment significantly increased pro-inflammatory cytokine release by splenocytes (A) or whole blood (B), whereas cytokines secreted by lung cells after ex vivo HKEC stimulation were not enhanced compared to PBS controls (C), Values are given as mean ± SD (n=9 mice/ group) and compared using two-way ANOVA and Bonferroni's multiple comparisons test. Figure 4 . Assessment of long-term cellular composition of blood and lung as well as neurological functions in GM-CSF and PBS treated stroke mice. Gait analysis 10 days after stroke showed similar maximum contact area (A) and stride length (B) of paws in GM-CSF treated mice but not in PBS-treated mice compared to before stroke. (C) GM-CSF mice also showed almost symmetry in corner turning 17 days after stroke onset, while PBS treated animals tended to turn to ipsilateral side. (D) Trend towards reduction in infarct size between day 1 and 14 after MCAo between both treatment groups. (E) Thirty days after stroke onset GM-CSF treated stroke mice showed significantly higher white blood cells counts (WBC) with a trend towards higher counts also in lung (F) when compared to PBS treated mice. Values are given as box plot with whiskers or as mean ± SD (n=19 mice before stroke, n=9 MCAo+PBS, n=7 MCAo+GM-CSF) and compared using two-way ANOVA and
